Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.360 -0.020 (-0.31%)
Official Closing Price Updated: 7:00 PM EDT, Sep 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,023,428
Open 6.360
Bid (Size) 5.800 (2,000)
Ask (Size) 6.400 (200)
Prev. Close 6.380
Today's Range 6.230 - 6.470
52wk Range 4.360 - 14.06
Shares Outstanding 52,700,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
From Emergent BioSolutions
Via GlobeNewswire

Performance

YTD
-49.2%
-49.2%
1 Month
+41.3%
+41.3%
3 Month
-17.9%
-17.9%
6 Month
-21.3%
-21.3%
1 Year
-20.5%
-20.5%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions (NYSE:EBS) Beats Q2 Estimates, but Stock Drops on NARCAN Impairment and Restructuring Costs ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Emergent Biosolutions Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings Economy
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
From Emergent BioSolutions
Via GlobeNewswire

Frequently Asked Questions

Is Emergent BioSolutions Inc. Common Stock publicly traded?
Yes, Emergent BioSolutions Inc. Common Stock is publicly traded.
What exchange does Emergent BioSolutions Inc. Common Stock trade on?
Emergent BioSolutions Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Emergent BioSolutions Inc. Common Stock?
The ticker symbol for Emergent BioSolutions Inc. Common Stock is EBS on the New York Stock Exchange
What is the current price of Emergent BioSolutions Inc. Common Stock?
The current price of Emergent BioSolutions Inc. Common Stock is 6.360
When was Emergent BioSolutions Inc. Common Stock last traded?
The last trade of Emergent BioSolutions Inc. Common Stock was at 09/15/26 07:00 PM ET
What is the market capitalization of Emergent BioSolutions Inc. Common Stock?
The market capitalization of Emergent BioSolutions Inc. Common Stock is 335.17M
How many shares of Emergent BioSolutions Inc. Common Stock are outstanding?
Emergent BioSolutions Inc. Common Stock has 335M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.